Reardon Tighe

SEC source: 0001415889-24-015676 · form4-06052024_110615.xml · nonDerivative · entry 2

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures SPV I, L.P.

Disclosed balance after: 3,340,018

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.

SEC source: 0001415889-24-015676 · form4-06052024_110615.xml · nonDerivative · entry 1

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures I, LP

Disclosed balance after: 633,673

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.

SEC source: 0001209191-24-000435 · doc4.xml · derivative · entry 1

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,000

Underlying: Common Stock · 157,000 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-23-055352 · doc4.xml · nonDerivative · entry 1

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 849,854

F1 · ownership.nature: The shares are directly held by Avalon BioVentures I, LP (ABV I). Avalon BioVentures GP LLC (ABV GP) is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.

SEC source: 0001209191-23-001882 · doc4.xml · derivative · entry 1

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-22-001830 · doc4.xml · derivative · entry 1

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,750

Underlying: Common Stock · 116,750 shares

Expires 2032-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2023 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-21-041041 · doc4.xml · derivative · entry 6

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,153,238 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.nature: Shares are held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is Chief Financial Officer of Avalon Ventures and shares voting and investment power with respect to the shares held by ABV SPV. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. if any.

SEC source: 0001209191-21-041041 · doc4.xml · derivative · entry 5

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,696,843 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.nature: Shares are held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is Chief Financial Officer of Avalon Ventures and shares voting and investment power with respect to the shares held by ABV SPV. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. if any.

SEC source: 0001209191-21-041041 · doc4.xml · nonDerivative · entry 4

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,479,492

F3 · kind: The shares were purchased in the Issuer's initial public offering.

F2 · ownership.nature: Shares are held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is Chief Financial Officer of Avalon Ventures and shares voting and investment power with respect to the shares held by ABV SPV. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. if any.

SEC source: 0001209191-21-041041 · doc4.xml · nonDerivative · entry 3

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,850,081

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.nature: Shares are held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is Chief Financial Officer of Avalon Ventures and shares voting and investment power with respect to the shares held by ABV SPV. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. if any.

SEC source: 0001209191-21-041041 · doc4.xml · nonDerivative · entry 2

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,696,843

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.nature: Shares are held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is Chief Financial Officer of Avalon Ventures and shares voting and investment power with respect to the shares held by ABV SPV. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. if any.

SEC source: 0001209191-20-004927 · doc4.xml · derivative · entry 4

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2028-12-05

F3 · derivative.exercise_date: This option, which provided for vesting of 100% of the shares subject to the option upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,710,000.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).

SEC source: 0001209191-20-004927 · doc4.xml · derivative · entry 3

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,723 shares

Expires 2028-08-29

F2 · derivative.exercise_date: This option, which was immediately exercisable, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,186,289.28, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).

SEC source: 0001209191-20-004927 · doc4.xml · nonDerivative · entry 2

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Avalon X SPV I, L.P.

Disclosed balance after: 0

F1 · ownership.nature: The Reporting Person is Chief Financial Officer and Partner of Avalon X SPV GP LLC, general partner of Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any.

SEC source: 0001209191-20-004927 · doc4.xml · nonDerivative · entry 1

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001209191-18-062518 · doc4.xml · derivative · entry 4

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Avalon X SPV I, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,136,631 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1.60224-to-1 basis. The shares have no expiration date.

F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1.60224-to-1 basis. The shares have no expiration date.

F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1.60224-to-1 basis. The shares have no expiration date.

F2 · ownership.nature: The Reporting Person is Chief Financial Officer and Partner of Avalon X SPV GP LLC, general partner of Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any.

SEC source: 0001209191-18-062518 · doc4.xml · nonDerivative · entry 2

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Avalon X SPV I, L.P.

Disclosed balance after: 1,682,086

F3 · kind: The shares were purchased at the Issuer's initial public offering.

F2 · ownership.nature: The Reporting Person is Chief Financial Officer and Partner of Avalon X SPV GP LLC, general partner of Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any.

SEC source: 0001209191-18-062518 · doc4.xml · nonDerivative · entry 1

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Avalon X SPV I, L.P.

Disclosed balance after: 1,136,631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1.60224-to-1 basis. The shares have no expiration date.

F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1.60224-to-1 basis. The shares have no expiration date.

F2 · ownership.nature: The Reporting Person is Chief Financial Officer and Partner of Avalon X SPV GP LLC, general partner of Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any.

SEC source: 0001209191-18-061570 · doc4.xml · derivative · entry 1

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2028-12-05

F1 · derivative.exercise_date: 100% of the shares subject to the option vest upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world.